Package Leaflet: Information for the User
Brilique 90mg orodispersible tablets
ticagrelor
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the pack
What is Brilique
Brilique contains the active substance ticagrelor. It belongs to a group of medicines called antiplatelet agents.
What Brilique is used for
Brilique, in combination with acetylsalicylic acid (another antiplatelet agent), should only be used in adults. You have been prescribed this medicine because you have had:
This medicine reduces the risk of you having another heart attack, a stroke or of dying from a heart or blood vessel-related illness.
How Brilique works
Brilique works on cells called ‘platelets’ (also called thrombocytes). These very small blood cells help stop bleeding by clumping together to block tiny holes in blood vessels that are cut or damaged.
However, platelets can also form clots inside damaged blood vessels in the heart and brain. This can be very dangerous because:
Brilique helps prevent platelets from clumping together. This reduces the chance of a blood clot forming that could block blood flow.
Do not take Brilique if:
Do not take Brilique if any of the above applies to you. If you are unsure, consult your doctor or pharmacist before taking this medicine.
Warnings and precautions
Consult your doctor or pharmacist before taking Brilique if:
If any of the above applies to you (or if you are unsure), consult your doctor or pharmacist before taking this medicine.
If you are taking Brilique and heparin:
Children and adolescents
Brilique is not recommended for children and adolescents under 18 years of age.
Using Brilique with other medicines
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. This is because Brilique may affect the way some medicines work and some medicines may affect Brilique.
Tell your doctor or pharmacist if you are taking any of the following medicines:
In particular, tell your doctor or pharmacist if you are taking any of the following medicines that increase the risk of bleeding:
Tell your doctor that, because you are taking Brilique, you may have a higher risk of bleeding if your doctor gives you fibrinolytics, often referred to as ‘clot dissolvers’, such as streptokinase or alteplase.
Pregnancy and breast-feeding
Brilique should not be used if you are pregnant or can become pregnant. Women should use appropriate contraceptive methods to prevent pregnancy while taking this medicine.
Consult your doctor before taking this medicine if you are breast-feeding. Your doctor will explain the benefits and risks of taking Brilique during this time.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Brilique is unlikely to affect your ability to drive or use machines. If you feel dizzy or confused while taking this medicine, be careful while driving or using machines.
Sodium content
This medicine contains less than 1 mmol of sodium (23 mg) per dose, which is essentially ‘sodium-free’.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
How much to take
Taking Brilique with other medicines for blood clotting
Your doctor will also usually prescribe acetylsalicylic acid for you. This is a substance found in many medicines used to prevent blood clotting. Your doctor will tell you how much to take (usually between 75-150 mg daily).
How to take Brilique
Do not open the blister until you are ready to take your medicine.
If you are in hospital, this tablet may be given to you mixed with a little water and through a tube in your nose (nasogastric tube).
If you take more Brilique than you should
If you take more Brilique than you should, contact your doctor or go to hospital immediately. Take the medicine pack with you. You may have a higher risk of bleeding.
If you forget to take Brilique
If you stop taking Brilique
Do not stop taking Brilique without consulting your doctor. Take this medicine regularly and for as long as your doctor tells you. If you stop taking Brilique, you may increase your risk of having another heart attack or a stroke or of dying from a heart or blood vessel-related illness.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may occur with Brilique:
Brilique affects blood clotting, so most side effects are related to bleeding. Bleeding can occur anywhere in the body. Some level of bleeding is common (such as bruising and nosebleeds). Serious bleeding is rare but can be life-threatening.
Tell your doctor immediately if you notice any of the following - you may need urgent medical treatment:
Tell your doctor if you notice any of the following:
Other possible side effects
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Frequency not known (cannot be estimated from the available data)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and on the carton after EXP/CAD. The expiry date refers to the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition ofBrilique
mannitol (E421), microcrystalline cellulose (E460), crospovidone (E1202), xylitol (E967), anhydrous calcium hydrogen phosphate (E341), sodium stearyl fumarate, hydroxypropylcellulose (E463), anhydrous colloidal silica.
Appearance and Packaging of the Product
The buccal dispersible tablets are round, flat, with beveled edges, white to pale pink in color, marked with a "90" above a "TI" on one side.
Brilique is available in:
Not all pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
AstraZeneca AB
SE-152 57 Södertälje
Sweden
Manufacturer:
AstraZeneca AB
Gärtunavägen
SE-151 85 Södertälje
Sweden
For further information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:
Belgium/Belgique/Belgien AstraZeneca S.A./N.V. Tel: +32 2 370 48 11 | Lithuania UAB AstraZeneca Lietuva Tel: +370 5 2660550 |
Luxembourg/Luxemburg NV AstraZeneca SA Tél/Tel: +32 2 370 48 11 | |
Czech Republic AstraZeneca Czech Republic s.r.o Tel: +420 222 807 111 | Hungary AstraZeneca kft Tel.: +36 1 883 6500 |
Denmark AstraZeneca A/S Tlf: +45 43 66 64 62 | Malta Associated Drug Co. Ltd Tel: +356 2277 8000 |
Germany AstraZeneca GmbH Tel: +49 40 809034100 | Netherlands AstraZeneca BV Tel: +31 85 808 9900 |
Estonia AstraZeneca Tel: +372 6549 600 | Norway AstraZeneca AS Tlf: +47 21 00 64 00 |
Greece AstraZeneca A.E. Τηλ: +30 2 106871500 | Austria AstraZeneca Österreich GmbH Tel: +43 1 711 31 0 |
Spain AstraZeneca Farmacéutica Spain, S.A. Tel: +34 91 301 91 00 | Poland AstraZeneca Pharma Poland Sp. z o.o. Tel.: +48 22 245 73 00 |
France AstraZeneca Tél: +33 1 41 29 40 00 | Portugal AstraZeneca Produtos Farmacêuticos, Lda. Tel: +351 21 434 61 00 |
Croatia AstraZeneca d.o.o. Tel: +385 1 4628 000 | Romania AstraZeneca Pharma SRL Tel: +40 21 317 60 41 |
Ireland AstraZeneca Pharmaceuticals (Ireland) DAC Tel: +353 1609 7100 | Slovenia AstraZeneca UK Limited Tel: +386 1 51 35 600 |
Iceland Vistor hf Sími: +354 535 7000 | Slovak Republic AstraZeneca AB o.z. Tel: +421 2 5737 7777 |
Italy AstraZeneca S.p.A. Tel: +39 02 00704500 | Finland AstraZeneca Oy Puh/Tel: +358 10 23 010 |
Cyprus Αλκήτωρ Φαρµακευτικ? Λτδ Τηλ: +357 22490305 | Sweden AstraZeneca AB Tel: +46 8 553 26 000 |
Latvia SIA AstraZeneca Latvija Tel: +371 67377 100 | United Kingdom(Northern Ireland) AstraZeneca UK Ltd Tel: +44 1582 836 836 |
Date of the Last Revision of thisLeaflet:
Other Sources of Information
Detailed information on this medicinal product is available on the European Medicines Agency website http://www.ema.europa.eu.